Gaudium IVF and Women Health Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Healthcare Services | Market Cap: ₹953 Cr
The company expects a revenue growth guidance of around 30% year-on-year for FY27, consistent with historical performance. The company guides for a 30% year-on-year revenue growth for FY27, consistent with its historical performance.
From Gaudium IVF and Women Health Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹115
Market Cap
₹953 Cr
P/E Ratio
38.9
Revenue Rank
Margin Rank
How does Gaudium IVF and Women Health Ltd rank in Healthcare Services?
Compare Gaudium IVF and Women Health Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Gaudium IVF and Women Health Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹30 Cr, net profit ₹8 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 2- →The company expects a revenue growth guidance of around 30% year-on-year for FY27, consistent with historical performance.
- →Q1 revenue grew by 9%, influenced by typical seasonal slowdowns in IVF treatments during quarter 1 due to heat-related patient behavior and ongoing integration of new technology and hubs.
- →Full-year growth target of 30% is supported by new hubs becoming operational, especially South Extension in New Delhi and upcoming locations.
- →The flagship Janakpuri center continues to grow roughly at 30% year-on-year.
- →Expansion includes opening 10 new hubs in FY27 and a women’s hospital in Lucknow (expected to commercialize in FY28-29).
- →Average revenue per patient, excluding low-value services, is approximately ₹4 lakhs.
- →The company is confident of maintaining EBITDA and PAT margins similar to FY26 by year-end, after accounting for upfront expansion costs.
📈 Profitability & Margins
Rank 3- →The company guides for a 30% year-on-year revenue growth for FY27, consistent with its historical performance.
- →Adjusted EBITDA margins are expected to be sustained at levels similar to FY26 by the end of FY27.
- →The current quarter's margin compression is attributed to a one-time heavy marketing push for AI tools SiD and ERICA; excluding these, margins align with steady-state operating profile.
- →Profit After Tax (PAT) and EBITDA are projected to grow in line with revenue growth, supported by higher patient volumes and clinical advancements.
- →Expansion of IVF hubs (27 planned) and integration of AI technologies are key drivers for future earnings growth.
- →The company maintains a debt-light structure, supporting financial flexibility for expansion without compromising profitability.
- →Earnings Per Share (EPS) growth is implied to follow the upward revenue and profit trajectory, though specific EPS guidance is not provided.
🏗️ Capital Expenditure Plans
Yes- →**Current FY27 Capex:** ₹25 crores planned for 10 new IVF hubs, averaging ₹2.5 crores per hub (₹1 crore construction + ₹1.5 crores lab machinery). Funded mainly through IPO proceeds and internal accruals.
- →**Gaudium Women Hospital, Lucknow:** Board approved up to ₹15 crores for project cost, to be incurred progressively over setup and commissioning in FY28-FY29. Funded mainly through internal accruals, not IPO proceeds.
- →**Capex Strategy:** Focus on a debt-light, capital-efficient, asset-light hub-and-spoke rollout.
- →**Expansion Plan:** Includes 19 new IVF centres and continued ramp-up of new hubs.
- →**Financial Position:** Robust and debt-light balance sheet post-IPO, with ₹8.12 crores cash against ₹6.74 crores borrowings and a low debt-to-equity ratio (~0.04).
💰 Fundraising & Capital Structure
No information- →No current or planned fundraising through debt or equity is mentioned.
- →The company maintains a debt-light structure with a low consolidated debt-to-equity ratio of approximately 0.04 times.
- →Expansion plans, including the capex of ₹25 crores for new IVF hubs and ₹15 crores for the Gaudium Women Hospital in Lucknow, are funded primarily through IPO proceeds and internal accruals.
- →Specifically, the Lucknow hospital project will be financed using internal accruals, not IPO proceeds.
- →The company emphasizes financial discipline and intends to fund its expansion without increasing debt, leveraging its strong balance sheet and cash reserves.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Gaudium IVF and Women Health Ltd Q1 FY27 results?
The company expects a revenue growth guidance of around 30% year-on-year for FY27, consistent with historical performance. The company guides for a 30% year-on-year revenue growth for FY27, consistent with its historical performance.
What is Gaudium IVF and Women Health Ltd share price analysis?
Gaudium IVF and Women Health Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 38.9 with a market cap of ₹953 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gaudium IVF and Women Health Ltd planning capital expenditure?
Current FY27 Capex:** ₹25 crores planned for 10 new IVF hubs, averaging ₹2.5 crores per hub (₹1 crore construction + ₹1.5 crores lab machinery).
Keep Gaudium IVF and Women Health Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.